Identification of Biomarkers for Early Detection of Pancreatic Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier:
NCT00897494
First received: May 9, 2009
Last updated: March 4, 2014
Last verified: March 2014

May 9, 2009
March 4, 2014
February 2005
November 2009   (final data collection date for primary outcome measure)
  • Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer [ Time Frame: Upon collection when patient agrees to provide a one time venous blood collection ] [ Designated as safety issue: No ]
  • Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis [ Time Frame: After separation from the plasma ] [ Designated as safety issue: No ]
  • Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer [ Designated as safety issue: No ]
  • Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00897494 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Identification of Biomarkers for Early Detection of Pancreatic Cancer
Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.

OBJECTIVES:

  • Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer.
  • Analyze serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis.

OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS).

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Venous blood

Non-Probability Sample

Venous blood collection samples from newly dianosed

Pancreatic Cancer
  • Genetic: protein expression analysis
    Venous blood collection
  • Other: laboratory biomarker analysis
    Venous blood collection
  • Other: mass spectrometry
    Venous blood collection
  • Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry
    Venous blood collection
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
75
April 2011
November 2009   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of pancreatic cancer

    • Newly diagnosed disease
  • Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos Cancer Institute or its affiliates

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00897494
CDR0000479140, P30CA022453, WSU-C-2737, WSU-013105MP2E
No
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Fazlul Sarkar, MD Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP